Table 1. Study design for testing immunogenicity of αDCIR.HIV5pep and αCD40.HIV5pep vaccines.
| W0 | W2 | W8 | W10 | W12 | W14 | W16 | W18 | W24 | W26 | |
| G1 | MVA | MVA |
αDCIR.HIV5pep ⁄ poly-ICLC |
αDCIR.HIV5pep ⁄ poly-ICLC |
αDCIR.HIV5pep ⁄ poly-ICLC |
|||||
| G2 | MVA | MVA |
αCD40.HIV5pep ⁄ poly-ICLC |
αCD40.HIV5pep ⁄ poly-ICLC |
αCD40.HIV5pep ⁄ poly-ICLC |
|||||
| W0 | W2 | W4 | W6 | W12 | W14 | W22 | W24 | |||
| G3 |
αDCIR.HIV5pep ⁄ poly-ICLC |
αDCIR.HIV5pep ⁄ poly-ICLC |
αDCIR.HIV5pep ⁄ poly-ICLC |
MVA | ||||||
| G4 |
αCD40.HIV5pep ⁄ poly-ICLC |
αCD40.HIV5pep ⁄ poly-ICLC |
αCD40.HIV5pep ⁄ poly-ICLC |
MVA | ||||||
The table shows immunization regimens used within the four groups (G1-4) in this study each group had six animals. In G1-2, MVA GagPolNef (4.5x107 pfu per animal) was administered subcutaneously (s.c.). The DC-targeting vaccines (250 μg per animal at each time point) were administered intradermally (i.d.). Poly-ICLC co-administration (1 mg per animal, s.c.) was adjacent to the site of DC-targeting vaccine administration. MVA = MVA GagPolNef. Samplings for fresh and frozen peripheral blood mononuclear cells (PBMC) and plasma were at the weeks (W) indicated by shading. Note the timelines for G1-2 are different from G3-4.